DRG Epidemiology’s coverage of cystic fibrosis (CF) comprises epidemiological estimates of key patient populations in 41 countries worldwide. We report the prevalence of CF for each country, as well as annualized case counts projected to the national population.
Most patient populations in the mature pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) are forecast over a period of 20 years; patient populations in the other countries are forecast over a period of 10 years.
DRG Epidemiology’s CF forecast will answer the following question:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of CF over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, for the mature pharmaceutical markets, we provide a graph depicting the patient flow between or within different disease states. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.
DRG Epidemiology provides at least ten years of forecast data for the following CF patient populations:
- Incident cases of CF at birth.
- Diagnosed prevalent cases of CF.
Note: Coverage may vary by country and region.
- Europe Data
- Key Findings
- Diagnosed Prevalence of Cystic Fibrosis per 1,000 People of All Ages in 2017 and 2027
- Relative Sizes of the Contributing Factors to the Trend in Diagnosed Prevalent Cases of Cystic Fibrosis over the Next Ten Years
- Number of Additional Prevalent Cases of Cystic Fibrosis Incurred over 2017-2027 in the Countries Under Study
- Epidemiology Data
- Diagnosed Incident Cases of Cystic Fibrosis at Birth
- Diagnosed Prevalent Cases of Cystic Fibrosis
- Reference Materials
- Literature Review
- Literature Review
- Risk/Protective Factors
- Risk/Protective Factors for Cystic Fibrosis
- Literature Review
Author(s): Alison Isherwood, MSc, MRes, PhD; Ruchika Sharma, MPH
Alison Isherwood, , joined Decision Resources Group in 2008, as an Epidemiologist. Alison holds a in Medical Microbiology, Masters by Research in the Life Sciences and a in Epidemiology all from the University of Edinburgh. Prior to joining Decision Resources Inc., she was working on her in Molecular Virology, specializing on the severe acute respiratory syndrome (SARS) coronavirus, at the University of Reading. In her role at Decision Resources Group, Alison is currently an Epidemiology team lead as well as project managing custom epidemiology work in multiple therapy areas. Alison’s area of specialization at DRG is cancer, particularly breast cancer.
Ruchika Sharma joined Decision Resources Group as Associate Epidemiologist in May 2016. She performs fully documented systematic reviews of both published and grey literature on the epidemiology of assigned diseases and their risk factors to estimate incidence/prevalence over a 10-30 year period. She produces analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets. She holds a Master of Public Health degree from School of Public Health, Post-Graduate Institute of Medical Education and Research, and a Bachelor of Dental Surgery from MN DAV Dental College & has previously worked as a dental surgeon and as a Fellow at the National Health Systems Resource Centre, where she supported the preparation of National Health Accounts - Guidelines for India 2016.